Bank of America
ITRM

Bank of America’s Iterum Therapeutics ITRM Stock Holding History

Bank of America’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-105
Closed -$8K – 7254
2018
Q4 		$8K Buy
105
+103
+5,150% +$9.75K ﹤0.01% 6675
2018
Q3 		$0 Buy
+2
New +$261 ﹤0.01% 7360

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return

Bank of America's ITRM Position: Q1 2019 in Review

Bank of America sold out of Iterum Therapeutics (ITRM) in Q1 2019, closing a stake of 105 shares — an estimated $8K sold.

Bank of America first reported a position in ITRM in Q3 2018 and held it in 2 quarters. The position peaked at $8K in Q4 2018. 18 funds tracked by Wall St. Rank hold ITRM as of Q1 2019.

  • Bank of America reported no remaining Iterum Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Bank of America sold 105 Iterum Therapeutics shares in Q1 2019, an estimated $8K.
  • Bank of America first reported a position in Iterum Therapeutics in Q3 2018 and held it in 2 quarters.
  • Bank of America's Iterum Therapeutics position peaked at $8K in Q4 2018.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2019.

Based on Bank of America's 13F filing for Q1 2019, filed 15 May 2019.